Sheng Deng

Sheng Deng

Auto-generated profile, based on publicly available information

Sheng Deng

Central South University

Research Focus & Metrics

Academic Career Length

23Years (2004-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
6 June 2016 in Nature Genetics
Verified
Journal Article
Closed access
PDF file
HDHan-Xiang Deng
Han-Xiang Deng
YSYong Shi
Yong Shi
YYYi Yang
Yi Yang
KAKreshnik B Ahmeti
Kreshnik B Ahmeti
NMNimrod Miller
Nimrod Miller
TSTeepu Siddique
Teepu Siddique

24 October 2007 in Clinical and Experimental Pharmacology and Physiology
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
YHYi‐Jing He
Yi‐Jing He
ZGZhou Gan
Zhou Gan
LFLan Fan
Lan Fan
QLQing Li
Qing Li
HZHh Zhou
Hh Zhou

1 January 2014 in Expert Reviews in Molecular Medicine
Verified
Journal Article
Closed access
HDHao Deng
Hao Deng
HXHong Xia
Hong Xia
SDSheng Deng
Sheng Deng
Humans and other vertebrates exhibit left–right (LR) asymmetric arrangement of the internal organs, and failure to establish normal LR asymmetry leads to internal laterality disorders, includingsitus inversusandheterotaxy.Situs inversusis complete mirror-imaged arrangement of the internal organs along LR axis, whereasheterotaxyis abnormal arrangement of the internal thoraco-abdominal organs across LR axis of the body, most of which are associated with complex cardiovascular malformations. Both disorders are genetically heterogeneous with reduced penetrance, presumably because of monogenic, polygenic or multifactorial causes. Research in genetics of LR asymmetry disorders has been extremely prolific over the past 17 years, and a series of loci and disease genes involved insitus inversusandheterotaxyhave been described. The review highlights the classification, chromosomal abnormalities, pathogenic genes and the possible mechanism of human LR asymmetry disorders.

18 April 2007 in British Journal of Clinical Pharmacology
Verified
Journal Article
Closed access
PDF file
WZWei Zhang
Wei Zhang
BCBi‐Lian Chen
Bi‐Lian Chen
VOVural Ozdemir
Vural Ozdemir
YHYi‐Jing He
Yi‐Jing He
GZGan Zhou
Gan Zhou
HZHh Zhou
Hh Zhou

1 April 2022 in Annals of Translational Medicine
Verified
Journal Article
Open access
PDF file
LSLi Shao
Li Shao
YGYin-Ping Guo
Yin-Ping Guo
LWLi Wang
Li Wang
MCMan-Yun Chen
Man-Yun Chen
WZWei Zhang
Wei Zhang
WHWei-Hua Huang
Wei-Hua Huang
Effects of ginsenoside compound K on colitis-associated colorectal cancer and gut microbiota profiles in mice Li Shao, Yin-Ping Guo, Li Wang, Man-Yun Chen, Wei Zhang, Sheng Deng, Wei-Hua Huang

22 February 2024 in JCI Insight
Verified
Journal Article
Open access
PDF file
YLYu-Jue Li
Yu-Jue Li
QGQi Guo
Qi Guo
MYMing-Sheng Ye
Ming-Sheng Ye
GCGuangPing Cai
GuangPing Cai
WXWen-Feng Xiao
Wen-Feng Xiao
YXYe Xiao
Ye Xiao
RNA-binding proteins (RBPs) interact with RNA and ubiquitously regulate RNA transcripts during their life cycle, playing a fundamental role in the progression of angiogenesis-related diseases. In the skeletal system, endothelium-dependent angiogenesis is indispensable for bone formation. However, the role of RBPs in endothelium-dependent bone formation is unclear. Here, we show that RBP–Y-box-binding protein 1 (YBX1) was strongly reduced in the bone vasculature of ovariectomy (OVX) mice. Endothelial cell–specific deletion of Ybx1 impaired CD31-high, endomucin-high (CD31 hi EMCN hi ) endothelium morphology and resulted in low bone mass whereas Ybx1 overexpression promoted angiogenesis-dependent osteogenesis and ameliorated bone loss. Mechanistically, YBX1 deletion disrupted CD31 , EMCN , and bone morphogenetic protein 4 ( BMP4 ) stability in an m5C-dependent manner and blocked endothelium-derived BMP4 release, thereby inhibiting osteogenic differentiation of bone mesenchymal stromal cells. Administration of recombinant BMP4 protein restored impaired bone formation in Ybx1 deletion mice. Tail vein injection of CD31-modified polyethylene glycol–poly (lactic-co-glycolic acid) carrying sciadopitysin, a natural YBX1 agonist, pharmacologically partially reversed CD31 hi EMCN hi vessels’ decline and improved bone mass in both OVX and aging animals. These findings demonstrated the role of RBP-YBX1 in angiogenesis-dependent bone formation and provided a therapeutic approach for ameliorating osteoporosis.